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wDITORIAL COMMENT
ou Only Get
o Many Heartbeats. . .*
eter R. Kowey, MD
ynnewood and Philadelphia, Pennsylvania
hese words, attributed apocryphally to Dr. Sam Levine, have
een passed along through several generations of his “off-
pring.” As happened so many times, Dr. Levine’s vast and
ncyclopedic clinical experience allowed him to anticipate and
ccurately predict what subsequently would be proven in
ell-done and exhaustive clinical trials. In this particular case,
r. Levine correctly intuited that a low heart rate (HR), no
atter the rhythm, would benefit the patient. We now know
hat a patient’s prognosis after myocardial infarction is closely
ied to spontaneous HR. Those with low HRs clearly outlive
hose with high rates. Low values reflect heightened vagal tone,
roven in the experimental laboratory to be cardioprotective,
educing vulnerability to ventricular fibrillation and opposing
he profibrillatory effects of heightened sympathetic stimula-
ion. High vagal tone is reflected in a myriad of parameters of
R variability, a highly powerful predictor of outcome that has
een poorly embraced by practicing cardiologists. One reason
or this lack of acceptance may be that the resting HR itself is
ard to outdo as a risk predictor in post-infarction patients and
n other forms of heart disease such as heart failure, wherein more
oderate heart rhythms auger better than those that are allegro.
See page 1201
It is not surprising that the Atrial Fibrillation Follow-up
nvestigation of Rhythm Management (AFFIRM) investi-
ators made the efficiency of HR control a primary focus of
heir research efforts. They and others proved incontrovert-
bly that rate control using drugs or other interventions is a
easonable treatment option in selected patients with atrial
brillation (AF) (1–4). So it was only logical that they then
ould move on to deliver detailed information about rate
ontrol in the report in this issue of the Journal (5). They
orrectly cite a wealth of literature that indicates that high
Rs are not good for patients with AF. There have been
any case reports and small series in which patients were
ound to have dramatic improvement of left ventricular
unction after recovery from what was certainly tachycardia-
elated cardiomyopathy (6). In fact, there are probably
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
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or AFFIRM. Dr. Kowey received no remuneration from the trial and was not the
hite’s principal investigator.rders of magnitude more cases in which left ventricular
unction improved, but not as dramatically, not only because
f rate control but also because the ventricular response was
egularized (7). The exact mechanism by which tachycardia
auses deterioration in left ventricular function has not been
lucidated, but what is clear is that recovery is independent
f the method by which rate control is restored. In fact,
edical treatment, even with negatively inotropic medica-
ions, works as well as non-pharmacologic approaches.
Dr. Bernard Lown, Dr. Levine’s most famous disciple,
mphasized the importance of digitalis in high doses for this
ndication. The fact is that at the time that Lown and
evine promulgated the notion of rate control as the
referred strategy for AF patients, beta-blockers and non-
ihydropyridine calcium antagonists, mainstays of current
herapy, had not been invented yet. Acetyl-digitoxin was
heir favorite preparation, which not only slowed but also
egularized the ventricular rhythm in chronic AF patients,
hus contributing to symptom improvement. Lown also
avored this novel preparation of digitalis because it was only
artially detectable in commonly used digoxin assays. Thus,
hysicians who shared the care of Lown’s patients were less
ikely to reduce the dose of the drug based on a random high
lood level. Lown and Levine felt strongly that measure-
ents of digitalis plasma concentrations were not relevant
n patients who were receiving the drug for AF. Avoidance
f digitalis excess has been facilitated by serum assays in
atients with sinus rhythm, but they believed that the
entricular response rate itself was the most appropriate
bioassay” upon which to base dose adjustments. Conse-
uently, they used much larger doses than we use currently,
ith remarkably good results not only in terms of rate
ontrol but also with regard to rhythm smoothing. High
oses of digitalis appear to regularize AF, but the mecha-
ism for this interesting phenomenon is not clear and is not
ecessarily unique to digitalis preparations. Some have
hought that digitalis in high concentrations sensitizes the
pecialized conduction tissue in the atrium or the junction
o become the predominant and more regular pacemaker.
hatever the reason, once again clinical experience and
cumen antedated trial data. We now know that the
moothing of rhythm and control of rate that is afforded by
trioventricular (AV) node ablation and ventricular pacing is
ssociated with an improvement in ventricular performance
nd quality of life over and above what might be expected
ith rhythm control strategies (8).
The data from AFFIRM presented by Olshansky et al. (5)
s very interesting with this historical perspective. They found
number of interesting things that deserve emphasis. First,
bjective measures of rate control are important in assessing the
orth of any intervention. Unfortunately, there is no univer-
ally agreed-upon parameter for effective rate control. It is clear
hat HR should be assessed at rest as well as during effort, but
hat the target HR should be and during what level of exertion
as never been standardized. The authors chose a simple,
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Editorial Comment April 7, 2004:1209–10ffice-based clinical assessment (or the option of a Holter-
ased measurement) that appears to have been reliable and
airly reproducible. The authors also found that rate control is
ot as easy as many have assumed. Single-drug therapy failed
requently, multiple drugs failed sometimes, and frequent dose
itration to achieve optimal rate control was critical. All of this
affirms” that rate control, although conceptually simple,
hould not be taken lightly. Nevertheless, the strategy worked
airly well, with a good percentage of patients achieving the end
oint. This may help to explain why the rate control strategy
orked so well compared with rhythm control in AFFIRM
nd in the other three trials in which it was tested. It was not
urprising that beta-blockers were the most effective drugs in
he study and that they were highly useful in patients at rest or
ith activity. What was surprising, but in agreement with the
xperience of Lown and Levine, was how well digitalis per-
ormed, either as a single drug or when used in combination.
igitalis works better in the sedentary, elderly population than
n young active patients in whom its vagomimetic effects can be
vercome by the increases in sympathetic tone that accompany
igh activity levels. Because the elderly were well represented in
FFIRM, the good performance of digitalis is interpretable.
ut these comparative data must be put into context: the
election of rate-control therapy was not randomized or
linded, and comparisons of efficacy are therefore difficult,
specially given the great inequalities among groups with
egard to clinical characteristics. Prior treatment was also
iverse, but interesting, in that patients who were treated with
particular rate control drug before study entry tended to
ontinue using that drug in the study itself, a self-fulfilling
rophecy of efficacy. As one would have expected, certain drugs
ere used much more frequently in specific clinical syndromes,
ased on tolerance or efficacy for reasons other than rate
ontrol itself. For example, digitalis was used more frequently
han beta-blockers or calcium channel blockers in cardiomy-
pathy but not in hypertension. Atrioventricular node ablation
as not used as a parallel strategy but as a last resort interven-
ion in drug non-responders, which is its appropriate niche.
otably, AV node modification, now appropriately abandoned
s a dangerous rate-control strategy, was not used in the study.
As valuable as the data from this study are, there is much
e still do not know. We really do not know whether a rate
ontrol strategy can be applied to the most symptomatic
atients with AF. The AFFIRM study and its cousins
ecruited a large number of patients who were selected
ecause they were already fairly comfortable with their
rrhythmia. In addition, although we think that well-
ontrolled HRs are good for patients, we do not have hard
utcome data from any trial that show this incontrovertibly.
or example, we don’t know whether drug-induced rate
lowing is as beneficial prognostically as having slow HRs
rom high vagal tone. Neither AFFIRM nor any other trial
as shown that patients live longer, are hospitalized less, or
ave a higher quality of life as a function of HR control. It
ould be good to know if there should be a preferred order
f rate control therapy and whether any one approach isuperior in terms of these hard end points. Whether or not
hose data can be mined from the AFFIRM database, or
rom the results of any other trial(s), remains to be seen. The
act is that further refinement is unlikely. However, there is
t least the hope that we will have drugs available that effect
V nodal conduction in a more specific way than present-
ay therapy. For example, there is much interest both in
urine agonists that are more cardioselective and AV-node
elective than adenosine and in the possibility that these
ew compounds may have a long enough half-life and
ufficient bioavailability to be used orally (9).
Until new drugs and new data are available, it seems
ogical and reasonable to pursue rate control aggressively in
atients with AF no matter what long-term strategy is
ltimately pursued, and this approach is reflected in current
uidelines (10). Such conservatism is based on a wealth of
ositive clinical experience, now buttressed by a series of
ell-executed clinical trials for which we owe our fellow
linical scientists a debt of gratitude. Clearly, the old clinical
aw “You only get so many heart beats. . .you should save
ome for later in life” has more meaning than most of us
maybe even Levine and Lown) could have imagined.
eprint requests and correspondence: Dr. Peter R. Kowey,
ain Line Health Heart Center, 558 Lankenau MOB East, 100
ancaster Avenue, Wynnewood, Pennsylvania 19096. E-mail:
oweypr@mlhheart.org.
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